Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

NCT06196840 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

GENETIC: LX102 subretinal injection
BIOLOGICAL: Aflibercept intravitreal injection

Sponsor

Innostellar Biotherapeutics Co.,Ltd